• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Oncorus Shares Are Trading Lower By 25%; Here Are 20 Stocks Moving Premarket

    6/12/23 8:24:00 AM ET
    $AHI
    $AMTD
    $APRN
    $AUUD
    Package Goods/Cosmetics
    Consumer Discretionary
    Finance: Consumer Services
    Finance
    Get the next $AHI alert in real time by email

    Gainers

    • Auddia Inc. (NASDAQ:AUUD) shares rose 103.2% to $0.8809 in pre-market trading after gaining around 9% on Friday.
    • Infobird Co., Ltd (NASDAQ:IFBD) shares surged 69.1% to $2.46 in pre-market trading. Infobird recently regained compliance with Nasdaq minimum bid price requirement.
    • Chinook Therapeutics, Inc. (NASDAQ:KDNY) gained 66.8% to $40.01 in pre-market trading after the company agreed to be acquired by Novartis AG.
    • DatChat, Inc. (NASDAQ:DATS) gained 50.8% to $0.6101 in pre-market trading after gaining 8% on Friday.
    • Micromobility.com Inc. (NASDAQ:MCOM) shares rose 22.2% to $0.2811 in pre-market trading.
    • Tenax Therapeutics, Inc. (NASDAQ:TENX) shares climbed 16.2% to $0.38 in pre-market trading. Tenax Therapeutics recently announced it received a Notice of Allowance from the USPTO for its patent application covering the use of TNX-103 in pulmonary hypertension with heart failure with preserved ejection fraction.
    • AIM ImmunoTech Inc. (NYSE:AIM) shares gained 11.6% to $0.56 in pre-market trading after jumping 10% on Friday.
    • Advanced Health Intelligence Ltd. (NASDAQ:AHI) shares gained 11.1% to $2.42 in pre-market trading after jumping 581% on Friday.
    • Almaden Minerals Ltd. (NYSE:AAU) rose 9.1% to $0.1375 in pre-market trading.
    • InflaRx N.V. (NASDAQ:IFRX) rose 7% to $4.45 in pre-market trading after gaining 4% on Friday.

    Losers

    • Oncorus, Inc. (NASDAQ:ONCR) fell 24.9% to $0.0735 in pre-market. On June 7, Oncorus board unanimously approved dissolution and liquidation of company pursuant to a plan of liquidation and dissolution.
    • VirnetX Holding Corporation (NYSE:VHC) fell 13.5% to $0.3978 in pre-market trading after jumping 12% on Friday. VirnetX and Envoy signed an agreement to sell VirnetX's family of products, including VirnetX Matrix, to their 500 small-to-medium-size business customers in healthcare, manufacturing, banking and agriculture.
    • Blue Apron Holdings, Inc. (NYSE:APRN) fell 12.4% to $7.84 in pre-market trading. Blue Apron shares jumped 67% on Friday after the company announced the closing of its transaction, transferring its operational infrastructure to FreshRealm.
    • Cyxtera Technologies, Inc. (NASDAQ:CYXT) shares dropped 11.8% to $0.0564 in pre-market trading. Cyxtera recently received approvals from the U.S. Bankruptcy Court for the District of New Jersey for its "First Day" motions related to the Company’s voluntary Chapter 11 petitions filed on June 4, 2023.
    • Sientra, Inc. (NASDAQ:SIEN) shares dropped 11.3% to $2.20 in pre-market trading. Sientra shares jumped over
    • 42% on Friday the company announced FDA clearance for its AlloX2 Pro Tissue Expander.
    • AMTD IDEA Group (NYSE:AMTD) fell 10.7% to $1.50 in pre-market trading.
    • Yunji Inc. (NASDAQ:YJ) fell 10.6% to $0.1996 in pre-market trading after gaining around 15% on Friday.
    • Airspan Networks Holdings Inc. (NYSE:MIMO) shares fell 10.1% to $0.1963 in pre-market trading after dropping 5% on Friday.
    • Forza X1, Inc. (NASDAQ:FRZA) fell 9.9% to $2.81 in pre-market trading. Forza X1 announced that it received an initial purchase order from OneWater Marine indicating its intention to purchase 100 units of the company's upcoming 22-foot electric monohull boat worth approximately $12.
    • Medigus Ltd (NASDAQ:MDGS) fell 9.9% to $5.44 in pre-market trading after gaining around 12% on Friday. Medigus recently said it has sold its entire stake in ScoutCam for $6 million in cash.

     

    Now Read This: Traders More Optimistic After Dow Records Gains For Third Consecutive Session

    Get the next $AHI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHI
    $AMTD
    $APRN
    $AUUD

    CompanyDatePrice TargetRatingAnalyst
    Tenax Therapeutics Inc.
    $TENX
    3/17/2026$35.00Overweight
    Cantor Fitzgerald
    InflaRx N.V.
    $IFRX
    12/3/2025$2.00Outperform → Market Perform
    Leerink Partners
    Tenax Therapeutics Inc.
    $TENX
    9/8/2025$20.00Overweight
    Piper Sandler
    InflaRx N.V.
    $IFRX
    9/2/2025$6.00Buy
    H.C. Wainwright
    InflaRx N.V.
    $IFRX
    5/29/2025$2.00Strong Buy → Outperform
    Raymond James
    InflaRx N.V.
    $IFRX
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    Tenax Therapeutics Inc.
    $TENX
    10/24/2024$16.00Outperform
    Leerink Partners
    Tenax Therapeutics Inc.
    $TENX
    10/14/2024$16.00Buy
    Guggenheim
    More analyst ratings

    $AHI
    $AMTD
    $APRN
    $AUUD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

    Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aRSubstantial progress made toward Phase 2b readiness for izicopan in hidradenitis suppurativa (HS)InflaRx actively reviewing and considering additional development in ANCA‑associated vasculitis (AAV)To broaden izicopan signal-finding activities and expedite proof-of-concept studies into additional indications in inflammation and immunology (I&I), InflaRx intends to conduct a pharmacokinetic (PK) bridging study in China this yearActive dialog with potential collaborators to expedite the Company's total pipeline development goals continuesInflaRx

    3/19/26 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Auddia Announces LT350 Initiative to Power the Autonomous Vehicle Revolution with Distributed AI Datacenters

    Fulfills critical industry technology void and aligns with global shift toward autonomous mobility Distributed AI datacenters positioned for robotaxi and logistics fleets Data offload + charging in one location BOULDER, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Auddia Inc. (NASDAQ:AUUD) ("Auddia" or the "Company") today announced a major initiative to position its LT350 platform as the distributed compute backbone for the rapidly scaling autonomous vehicle (AV) industry. LT350, the company redefining AI infrastructure through modular, power-sovereign datacenter canopies, is aligning its platform with the global shift toward autonomous mobility. The announcement follows Nvidia's declara

    3/19/26 6:00:00 AM ET
    $AUUD
    EDP Services
    Technology

    Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

    DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Today's action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. Artelo Biosciences (NASDAQ:ARTL) expands ART27.13's clinical footprint into ophthalmology through a fully funded investigator-initiated study agree

    3/18/26 10:41:39 AM ET
    $AIM
    $ARTL
    $YYGH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Professional Services

    $AHI
    $AMTD
    $APRN
    $AUUD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Tenax Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $35.00

    3/17/26 8:15:05 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded InflaRx from Outperform to Market Perform and set a new price target of $2.00

    12/3/25 8:30:03 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Tenax Therapeutics with a new price target

    Piper Sandler initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $20.00

    9/8/25 8:59:21 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHI
    $AMTD
    $APRN
    $AUUD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/10/25 6:48:57 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $45,622 worth of shares (5,000 units at $9.12), increasing direct ownership by 940% to 2,766 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/5/25 5:46:32 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Giordano Christopher Thomas bought $20,000 worth of shares (2,605 units at $7.68) (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    11/20/25 6:38:51 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHI
    $AMTD
    $APRN
    $AUUD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Infobird Co. Ltd

    3 - Infobird Co., Ltd (0001815566) (Issuer)

    3/18/26 9:11:23 AM ET
    $IFBD
    Computer Software: Prepackaged Software
    Technology

    SEC Form 3 filed by Infobird Co. Ltd

    3 - Infobird Co., Ltd (0001815566) (Issuer)

    3/18/26 9:10:36 AM ET
    $IFBD
    Computer Software: Prepackaged Software
    Technology

    SEC Form 3 filed by Infobird Co. Ltd

    3 - Infobird Co., Ltd (0001815566) (Issuer)

    3/18/26 9:09:35 AM ET
    $IFBD
    Computer Software: Prepackaged Software
    Technology

    $AHI
    $AMTD
    $APRN
    $AUUD
    SEC Filings

    View All

    SEC Form 6-K filed by InflaRx N.V.

    6-K - InflaRx N.V. (0001708688) (Filer)

    3/19/26 7:45:03 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AMTD IDEA Group

    6-K - AMTD IDEA GROUP (0001769731) (Filer)

    3/10/26 4:01:10 PM ET
    $AMTD
    Finance: Consumer Services
    Finance

    SEC Form 10-K filed by Tenax Therapeutics Inc.

    10-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

    3/10/26 7:48:55 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHI
    $AMTD
    $APRN
    $AUUD
    Leadership Updates

    Live Leadership Updates

    View All

    Groupon Launches Board-Level Artificial Intelligence Committee and Appoints Amit Shah to Board of Directors

    Technology executive and AI entrepreneur to chair new committee as Company positions marketplace for the era of agentic commerceChicago, Illinois--(Newsfile Corp. - March 10, 2026) - Groupon, Inc. (NASDAQ:GRPN) today announced the appointment of Amit Shah to its Board of Directors, effective March 10, 2026, and the formation of a dedicated Artificial Intelligence Committee of the Board. Shah, a seasoned technology executive and AI entrepreneur, will serve as the Committee's inaugural Chair.With this action, Groupon becomes one of the first publicly traded consumer marketplaces to establish a board-level committee dedicated to artificial intelligence. The formation of the Committee reflects t

    3/10/26 4:15:00 PM ET
    $APRN
    $FLWS
    $GRPN
    Catalog/Specialty Distribution
    Consumer Discretionary
    Other Specialty Stores
    Advertising

    Auddia Reports Strong First 30 Days of Discovr Radio MVP Launch, Exceeding Internal Expectations

    Initial data demonstrates significant artist engagement and conversion beyond passive streaming listening Artist profile views by faidr listeners currently running at 3x original expectations BOULDER, Colo., March 05, 2026 (GLOBE NEWSWIRE) -- Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia" or the "Company"), an AI-first technology company that has built a proprietary AI platform for audio identification and classification to reinvent how consumers engage with audio, today announced initial performance results from the first 30 days of Discovr Radio's MVP offering and the corresponding engagement within the faidr app. Following the official launch of Discovr Radio on January 20, 2026,

    3/5/26 6:00:00 AM ET
    $AUUD
    EDP Services
    Technology

    Auddia Announces Restructuring of Engineering Team in Preparation for Business Combination

    Restructuring projected to reduce engineering costs by $750,000 annually Current lead AI engineer to join the AI engineering team at the holding company level upon closing of the proposed business combination Utilization of internal and dedicated outsourced engineering talent expected to significantly increase the speed of product development BOULDER, Colo., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia" or the "Company"), an AI first technology company that has built a proprietary AI platform for audio identification and classification to reinvent how consumers engage with audio, today announced a restructuring of its engineering team aimed at si

    8/25/25 6:12:00 AM ET
    $AUUD
    EDP Services
    Technology

    $AHI
    $AMTD
    $APRN
    $AUUD
    Financials

    Live finance-specific insights

    View All

    InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

    Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aRSubstantial progress made toward Phase 2b readiness for izicopan in hidradenitis suppurativa (HS)InflaRx actively reviewing and considering additional development in ANCA‑associated vasculitis (AAV)To broaden izicopan signal-finding activities and expedite proof-of-concept studies into additional indications in inflammation and immunology (I&I), InflaRx intends to conduct a pharmacokinetic (PK) bridging study in China this yearActive dialog with potential collaborators to expedite the Company's total pipeline development goals continuesInflaRx

    3/19/26 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx to Report Full Year 2025 Results on March 19, 2026

    JENA, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2025 on March 19, 2026, before the market opens. No conference call is planned. About InflaRxInflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C

    3/12/26 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AMTD L'Officiel expands successfully and globally with full legal rights and IP registrations

    PARIS and NEW YORK and LONDON, Jan. 28, 2026 /PRNewswire/ -- AMTD Group Inc. ("AMTD Group"), AMTD IDEA Group (NYSE:AMTD, SGX: HKB)), AMTD Digital Inc. (NYSE:HKD) and The Generation Essentials Group (", TGE", , NYSE:TGE, LSE: TGE), a subsidiary of AMTD Digital Inc., jointly announce continual successes in the ongoing protection of their global intellectual properties portfolio. AMTD Group is the 100% global owner of the L'Officiel and AMTD IDEA brands, which have been expanding rapidly through multi-faceted conduits on a global basis. ====== Our brands have strong global presen

    1/28/26 5:52:00 PM ET
    $AMTD
    $HKD
    $TGE
    Finance: Consumer Services
    Finance
    Newspapers/Magazines
    Consumer Discretionary

    $AHI
    $AMTD
    $APRN
    $AUUD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by AMTD IDEA Group

    SC 13G/A - AMTD IDEA GROUP (0001769731) (Subject)

    11/14/24 9:37:44 PM ET
    $AMTD
    Finance: Consumer Services
    Finance

    SEC Form SC 13G filed by Tenax Therapeutics Inc.

    SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/14/24 7:14:21 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care